What does Immatics do?
Immatics N.V. is a Nasdaq-listed clinical-stage biopharmaceutical company developing T-cell receptor, or TCR, immunotherapies for solid tumors. Its scientific premise is that many useful cancer targets sit inside tumor cells and appear on the cell surface only as peptide-HLA complexes. Immatics identifies those complexes, selects targets that are abundant on tumors and limited on healthy tissue, then engineers TCRs that can recognize them. The company describes its current strategic center as precision targeting of PRAME, a cancer-associated antigen expressed across more than 50 cancer types. The official company overview also explains its transatlantic structure spanning Tübingen, Munich and Houston.
Why is one operating segment not the same as one product?
Financially, management reviews Immatics as one research-and-development segment. Strategically, however, the portfolio contains several distinct economic options. Anzu-cel is a patient-specific cell therapy approaching a potential registration pathway in melanoma. IMA203CD8 is a second-generation cell therapy intended to broaden the target population. IMA402 is an off-the-shelf PRAME bispecific, while IMA401 targets MAGEA4/8 and can be combined with IMA402. The official pipeline therefore matters more than the accounting segment label when assessing risk and value.
How does the transatlantic operating model support the strategy?
This footprint is not merely geographic diversification. It connects university-originated immunology and target-discovery expertise with U.S. oncology centers, regulatory pathways and commercial infrastructure. For a cell-therapy company, operational control over manufacturing and vein-to-vein logistics can be as important as the molecule itself.
How does Immatics make money before product approval?
Immatics does not yet sell an approved medicine. Its reported revenue comes from strategic collaboration agreements, while most of the economic value in the wholly owned pipeline remains contingent on clinical success, regulatory approval and commercialization. Collaboration revenue is recognized under IFRS as research obligations are performed, often on a cost-to-cost basis. It can therefore move sharply between periods without indicating end-market demand.
What are the current revenue streams?
| Economic stream | How cash or revenue arises | Current relevance | Investor interpretation |
|---|---|---|---|
| Collaboration research | Upfront consideration and research funding recognized as work is completed | Moderna and Bristol Myers Squibb programs | Useful financing, but quarterly recognition is lumpy |
| Milestones | Payments tied to research, development, regulatory or commercial events | Potentially material but uncertain | Probability-weighted rather than treated as recurring sales |
| Royalties or profit share | Economics on partnered products if they reach market | No current product royalties | Long-duration option value |
| Wholly owned products | Future product revenue, led by anzu-cel if approved | Commercial launch targeted by the company for 2H 2027 | Largest potential value driver and largest execution burden |
What converts science into commercial economics?
The 2023 Moderna agreement illustrates the platform model: Immatics received a $120 million upfront payment and retained milestone and royalty opportunities across multiple mRNA-enabled programs. The strategic point is not only cash. Partner validation can fund discovery while allowing Immatics to concentrate internal capital on its most advanced PRAME assets.
Which clinical programs define Immatics' PRAME franchise?
The portfolio is designed around one target but several products, indications and delivery formats. That concentration can create scientific and operational leverage: target biology, assays, manufacturing know-how and physician education may be reused. It also creates correlation risk because an unexpected problem with PRAME biology, HLA presentation or TCR specificity could affect more than one program.
Why is anzu-cel the lead value driver?
| Program | Modality and target | Development position | Latest disclosed signal | Strategic role |
|---|---|---|---|---|
| Anzu-cel | Autologous PRAME TCR-T | Phase 3 SUPRAME in advanced cutaneous melanoma; separate uveal melanoma work | 56% confirmed ORR and 14.6-month median duration of response in the June 2026 Phase 1b update | Potential first commercial product |
| IMA203CD8 | Second-generation PRAME TCR-T with CD8 co-receptor | Phase 1 dose escalation and expansion | 63% ORR in gynecologic cancers at clinically relevant doses | Broaden PRAME cell therapy beyond melanoma |
| IMA402 | Off-the-shelf PRAME TCR bispecific | Phase 1; RP2D-range data planned for ESMO 2026 | Clinical update pending | Expand access without individualized manufacturing |
| IMA401 | MAGEA4/8 TCR bispecific | Phase 1 monotherapy and pembrolizumab combination | 29% confirmed ORR in 14 head-and-neck cancer patients at RP2D | Diversify target exposure and enable IMA401/IMA402 combination |
The June 2026 anzu-cel clinical update reported 33 heavily pretreated metastatic melanoma patients at the recommended Phase 2 dose, with 64% overall response, 91% disease control, 6.1-month median progression-free survival and 16.2-month median overall survival. These are early-stage, non-randomized data, but they explain why the randomized SUPRAME trial dominates the near-term thesis.
How do second-generation cell therapy and bispecifics widen the opportunity?
The IMA203CD8 ASCO update supports the hypothesis that PRAME can work across biologically different solid tumors, including ovarian cancer with lower PRAME expression. Meanwhile, the IMA401 data provide an off-the-shelf proof point and a rationale for combining two bispecifics in lung cancer. The portfolio therefore offers both depth around PRAME and diversification through modality and target.
What do the latest financial results show?
The first quarter of 2026 shows a company moving from platform-funded research toward late-stage clinical execution and commercial preparation. Collaboration revenue fell, while spending rose sharply as SUPRAME, other clinical programs and launch-readiness activities expanded. The relevant financial question is not whether current revenue covers costs; it does not. The question is whether liquidity can finance the next value-inflection points without excessive dilution.
What changed in the quarter ended March 31, 2026?
| Metric | Q1 2026 | Q1 2025 | Change | Interpretation |
|---|---|---|---|---|
| Collaboration revenue | €7.6M | €18.6M | 59% decline | Lower cost-to-cost recognition, not a product-sales signal |
| R&D expense | €59.2M | €41.9M | 41% increase | Clinical execution, especially anzu-cel and SUPRAME |
| G&A expense | €14.5M | €12.1M | 20% increase | Commercialization preparation and professional fees |
| Operating loss | €66.1M | €35.4M | Wider loss | Spending growth outpaced collaboration revenue |
| Operating cash outflow | €42.0M | €34.2M | 23% increase | Working-capital support partly softened the accounting loss |
The full Q1 2026 interim report shows direct external cell-therapy spending of €24.0 million versus €10.0 million a year earlier. That is a more informative signal than quarterly collaboration revenue because it reveals where management is allocating scarce capital.
What does the 2025 annual baseline add?
The full-year 2025 results reported a €196.4 million net loss, compared with a €15.2 million profit in 2024. That reversal is not evidence that an approved franchise deteriorated; it reflects the timing of collaboration accounting and higher internal investment. For valuation, normalized cash burn and program-level probability matter more than accounting profit in any single pre-commercial year.
Which turning points shaped Immatics' current strategy?
Immatics' evolution is best understood as a sequence of capability-building decisions. The company moved from academic target discovery to a transatlantic therapeutic platform, then used partnerships and public equity to finance increasingly advanced clinical programs. Each step changed the economics: early platform validation generated non-dilutive cash, while the current phase requires late-stage trial spending, manufacturing readiness and commercial infrastructure.
How did the company move from discovery science to a potential launch?
-
2000Founded as a University of Tübingen spinout, establishing the target-discovery and TCR-science foundation that still supports the pipeline.
-
2015Immatics US launched with MD Anderson in Houston, adding U.S. clinical and cell-manufacturing capabilities.
-
2020The ARYA business combination and Nasdaq listing supplied $253 million of transaction proceeds and funded broader clinical development.
-
2021IMA401 was licensed to Bristol Myers Squibb for $150 million upfront plus milestone and royalty potential, validating the TCER platform.
-
2023The Moderna multi-platform collaboration added $120 million upfront and connected Immatics' target data with mRNA-enabled therapeutics.
-
2024Immatics regained IMA401 rights and prepared the randomized SUPRAME Phase 3 trial, increasing both strategic control and funding needs.
-
2026Multiple ASCO datasets expanded clinical evidence across melanoma, gynecologic cancers, synovial sarcoma and head-and-neck cancer.
That transition changes the risk profile. Partnerships reduce financing pressure and validate scientific capabilities, but a wholly owned launch can create more value only if the company can manage regulatory filings, manufacturing consistency, treatment-center onboarding and reimbursement. The history therefore explains why rising G&A and manufacturing preparation are not peripheral costs; they are part of the strategy.
What gives Immatics a competitive advantage?
The potential moat is a linked system rather than a single patent. Immatics combines a large proprietary target database, mass-spectrometry-based identification of peptide-HLA targets, TCR discovery and engineering, two therapeutic modalities, translational assays and cell-manufacturing know-how. The integrated workflow can shorten the path from target selection to therapeutic candidate and may make it easier to reuse knowledge across programs.
Why do target discovery and TCR engineering matter?
The strongest resource-based argument is that target data, receptor libraries and accumulated assay knowledge are difficult to reproduce quickly. However, a scientific resource becomes a durable economic advantage only when it produces superior clinical outcomes, reliable manufacturing and defensible intellectual property. Immatics has meaningful clinical signals, but it has not yet crossed the approval and commercialization threshold.
Can manufacturing and portfolio design strengthen the moat?
Anzu-cel is an autologous product: each dose begins with a patient's cells, which must be collected, engineered, expanded, tested and returned. In-house commercial manufacturing preparation can improve control over capacity, quality and turnaround time, but it also raises fixed costs and execution risk. IMA402 offers a complementary off-the-shelf model that could reach more treatment centers with simpler logistics. This combination of individualized potency and scalable bispecific access is strategically attractive because it avoids dependence on one delivery format.
Who competes with Immatics, and where is it positioned?
Competition occurs at several levels: approved melanoma therapies, other engineered cell therapies, TCR bispecific platforms and alternative ways to stimulate anti-tumor immunity. Immatics' latest annual filing identifies companies such as Iovance, Immunocore, Replimune and Obsidian in relevant cell-therapy or melanoma markets, and a broader group including CDR-Life, Ectembly, Myrio Therapeutics, Crossbow Therapeutics, EnaraBio, CorreGene and Engimmune in TCR-bispecific development.
| Competitive arena | Representative pressure | Immatics' positioning | What decides the outcome |
|---|---|---|---|
| Advanced melanoma | Checkpoint combinations, TIL therapy, targeted agents and novel immunotherapies | PRAME-directed, one-time engineered TCR-T with randomized Phase 3 development | Progression-free survival, durability, safety, eligibility and center logistics |
| Solid-tumor cell therapy | TIL, CAR-T and competing TCR-T programs | Target-first platform plus evidence across several PRAME-positive tumors | Target prevalence, antigen escape, manufacturing reliability and treatment burden |
| TCR bispecifics | Multiple emerging pHLA-directed engager platforms | Half-life-extended TCER architecture and combination strategy | Therapeutic window, dosing convenience, depth of response and combinability |
| Platform partnering | Other discovery companies offering target databases or receptor engineering | Validated collaborations plus internally owned clinical programs | Partner economics, speed, reproducibility and intellectual-property freedom |
The competitive advantage will not be settled by the number of programs. It will be settled by comparative clinical benefit and execution. A randomized result that materially improves outcomes can outweigh logistical complexity; weak differentiation can make even elegant science commercially fragile. The 2025 Form 20-F is the key official source for the company's competition and risk discussion.
How strong are liquidity, capital allocation, and governance?
Immatics had €301.3 million of cash and €152.2 million of other financial assets on March 31, 2026. Together, those liquid resources represented about 83.5% of total assets and were roughly 8.2 times current liabilities. This is a strong near-term funding position for a clinical-stage company, but it is not excess cash in the conventional sense: Phase 3 trials, manufacturing validation, regulatory work and launch preparation can consume capital quickly.
How is the balance sheet being used?
| Capital-allocation item | Official figure | Period | Analytical meaning |
|---|---|---|---|
| Operating cash outflow | €42.0M | Q1 2026 | Core quarterly burn before investing and financing flows |
| Property and equipment payments | €0.8M | Q1 2026 | Lower than the prior-year quarter after major facility build-out |
| ATM gross proceeds | €21.6M | March 2026 | Extends runway but increases the share count |
| Public-offering gross proceeds | €107.2M | December 2025 | Financed late-stage development and extended stated cash reach into 2028 |
Free cash flow is not a stable operating KPI here, but a simple approximation is useful: Q1 2026 operating cash outflow of €42.0 million plus €0.8 million of property-and-equipment payments produced an approximate €42.8 million cash outflow before financing. The company also had no conventional interest-bearing debt disclosed in the quarter beyond lease liabilities, so dilution rather than debt service is the main financing trade-off.
Who owns the stock, and why does governance matter?
| Holder or governance fact | Economic stake or rule | Source period | Why it matters |
|---|---|---|---|
| T. Rowe Price Investment Management | 21.7M shares; 16.1% | Schedule 13G, March 31, 2026 | Large specialist institutional ownership can influence governance expectations and financing capacity |
| RTW Investments | 12.9M shares; 9.6% | 2026 Schedule 13G | A major healthcare-focused holder increases the role of institutional clinical judgment |
| Ordinary shares outstanding | 136.7M | March 31, 2026 | Up from 134.1M at year-end after ATM issuance and option exercises |
| Voting structure | One vote per share | 2026 AGM record-date rules | No disclosed dual-class super-voting structure; economic ownership aligns more directly with voting power |
Official ownership filings show concentrated healthcare-institution participation: T. Rowe Price's Schedule 13G and RTW's Schedule 13G document the largest disclosed positions used here. The 2026 AGM materials also show founder-CEO continuity and a one-tier Dutch board. The governance tension is straightforward: equity incentives help retain scarce clinical and technical talent, but repeated stock issuance and awards can dilute per-share value.
What opportunities and risks could change the story?
Immatics has several independent ways to create value, but most depend on clinical and regulatory evidence rather than near-term revenue growth. The largest opportunity is successful Phase 3 validation of anzu-cel, followed by a credible BLA and launch. The largest risk is that late-stage evidence fails to reproduce the response and durability seen in the smaller Phase 1b dataset.
Which opportunities have the highest strategic leverage?
The most current official catalyst schedule is the July 2026 ESMO announcement. It points to October updates for anzu-cel durability, IMA203CD8 across PRAME-positive tumors and IMA402 at the recommended Phase 2 dose range.
What could weaken the outlook?
| Risk | Transmission mechanism | Financial line affected | What to monitor |
|---|---|---|---|
| Clinical efficacy or safety failure | Randomized outcomes may differ from early single-arm data; adverse events can limit use | Pipeline value, impairment risk and future revenue | PFS, overall survival, durability, severe CRS or neurotoxicity |
| HLA and target eligibility | Anzu-cel requires HLA-A*02:01 and sufficient PRAME presentation | Addressable population and screening efficiency | Screen-failure rates and target-expression thresholds |
| Manufacturing execution | Autologous production may face capacity, quality, turnaround or supply-chain problems | Cost of goods, capex, launch timing and gross margin | Batch success, vein-to-vein time and commercial-site readiness |
| Financing and dilution | Sustained cash burn may require additional equity before self-funding operations | Shares outstanding and per-share value | Quarterly burn, ATM usage, stock compensation and runway guidance |
| Competition and reimbursement | Alternative melanoma treatments can improve, while payers may scrutinize complex one-time therapy economics | Adoption, price, selling cost and peak market share | Standard-of-care changes, center demand and payer coverage |
Two additional constraints deserve attention. First, collaboration revenue is concentrated and can decline when project costs or contract scope change, so it should not be extrapolated like subscription revenue. Second, the company reports in euros while holding significant U.S.-dollar liquidity, creating foreign-exchange volatility that can move financial income or expense without changing underlying trial progress.
Which KPIs should students and investors monitor?
Traditional revenue growth, gross margin and earnings-per-share screens are insufficient for a pre-commercial biotech company. The most decision-useful KPIs connect clinical probability, time, cash consumption and dilution. A strong dashboard should separate scientific evidence from financing capacity and commercial execution.
What operating metrics best explain progress?
How should the metrics be interpreted together?
A positive readout can raise probability of approval and peak-sales assumptions, but it may also increase spending because management must accelerate manufacturing and commercial preparation. Conversely, a quarter with lower cash burn is not automatically better if enrollment slowed or key programs were delayed. The correct framework links every euro of burn to a clinical milestone and every milestone to an updated probability-weighted cash-flow scenario.
This is why per-share analysis must remain dynamic. Immatics had 136.7 million ordinary shares outstanding at quarter-end and granted 1.1 million RSUs during Q1 2026. Those awards may be economically rational for retention, but a DCF should include expected dilution rather than divide by a static historical share count.
What matters most in an Immatics DCF?
A conventional single-path DCF is poorly suited to Immatics because current collaboration revenue is not the principal value driver and future product cash flows are binary, delayed and indication-specific. The better structure is a probability-adjusted pipeline model with separate scenarios for anzu-cel, IMA203CD8, IMA402, IMA401 and partnered programs. Each scenario should include eligible patients, diagnosis and HLA screening, treatment-center capacity, price, penetration, manufacturing cost, commercial expense, probability of approval and launch timing.
The Immatics thesis rests on whether a differentiated PRAME platform can become a reproducible commercial franchise before cash burn and dilution absorb too much of the value.
- What supports the story: multi-program clinical evidence, a randomized Phase 3 lead asset, two therapeutic modalities, proprietary target and TCR capabilities, major institutional ownership and liquid resources that management says extend into 2028.
- What could weaken it: randomized data that fail to confirm early responses, HLA-limited eligibility, manufacturing or launch delays, competitive improvements, reimbursement friction and repeated equity issuance.
- What to monitor next: SUPRAME event timing, the October 2026 clinical updates, IMA203CD8 dose selection, IMA402's therapeutic window, quarterly operating cash outflow, manufacturing readiness and the fully diluted share count.
For students and researchers, Immatics is a useful case study in platform strategy, vertical integration and real-options valuation. For investors, the essential discipline is to separate attractive early clinical signals from the probability, time and capital required to convert them into durable free cash flow. The company is financially equipped to pursue that conversion, but the decisive evidence remains clinical and operational rather than accounting-based.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.